DoD tests AI models that make it easy to switch from vendors like Palantir
LISBON - Angle plc (AIM:AGL OTCQX:ANPCY) presented data on Tuesday for a new blood test that monitors androgen receptor (AR) expression in prostate cancer patients, according to a company press release.
The test uses Angle’s Parsortix system to isolate circulating tumor cells (CTCs) from blood samples, allowing physicians to assess AR expression levels. The androgen receptor plays a key role in prostate cancer progression and can develop resistance to current treatments.
In laboratory testing, the assay demonstrated the ability to detect changes in AR expression when prostate cancer cells were exposed to different drug concentrations. The test showed a reduction in AR-positive cells from over 80% in untreated samples to under 20% at the highest drug level.
The company also validated the test using blood samples from 20 patients with metastatic castration-resistant prostate cancer. Half of these patients had detectable CTCs, all of which expressed the androgen receptor, enabling assessment of expression levels.
The new assay addresses monitoring needs in prostate cancer treatment, particularly for patients developing resistance to therapy. According to the company, the AR inhibitor market is projected to reach $9.8 billion by 2032, with at least 130 ongoing clinical studies targeting this pathway.
Angle’s test is now available to pharmaceutical companies for biomarker assessment in clinical trials involving AR-targeted therapies.
The presentation was made at the European Association for Cancer Research Congress in Lisbon, which runs from June 16-19, 2025.
The test is currently available for research use only and not for diagnostic procedures.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.